Shanghai EpimAb Biotherapeutics Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Shanghai EpimAb Biotherapeutics Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Shanghai EpimAb Biotherapeutics Co.: 2 sponsored US clinical trials, 1 recruiting.
Shanghai EpimAb Biotherapeutics Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Gastrointestinal Carcinoid Tumor, with 1 trials.
Mid-pack sponsor footprint
Shanghai EpimAb Biotherapeutics Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Shanghai EpimAb Biotherapeutics Co. pipeline
1 recruiting of 2 indexed (50% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Metastatic Gastrointestinal Carcinoid Tumor (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shanghai EpimAb Biotherapeutics Co.: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Shanghai EpimAb Biotherapeutics Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Shanghai EpimAb Biotherapeutics Co. page
2 registered trials is a research-attention snapshot, not an endorsement of Shanghai EpimAb Biotherapeutics Co. or any single study.
- 1 of Shanghai EpimAb Biotherapeutics Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastatic Gastrointestinal Carcinoid Tumor is the condition Shanghai EpimAb Biotherapeutics Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Gastrointestinal Carcinoid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Shanghai EpimAb Biotherapeutics Co. pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.